Core Insights - Jade Biosciences reported strong momentum at the end of 2025, with significant advancements in its clinical pipeline and a solid financial position [2][8]. Pipeline and Corporate Updates - JADE101 is a selective anti-APRIL monoclonal antibody targeting IgA nephropathy, with Phase 1 healthy volunteer interim data expected in Q2 2026 and a Phase 2 trial anticipated to begin mid-2026 [3][9]. - JADE201, an anti-BAFF-R monoclonal antibody, is set to enter a first-in-human study for rheumatoid arthritis in Q2 2026, with interim data expected in 2027 [4][8]. - JADE301, an undisclosed antibody program, is projected to start its first-in-human clinical trial in the first half of 2027, with more details to be revealed in H2 2026 [5][8]. Financial Results - As of December 31, 2025, Jade had cash, cash equivalents, and investments totaling approximately $336 million, providing a runway into the first half of 2028 [12][8]. - Research and Development (R&D) expenses for Q4 2025 were $28.5 million, up from $17.6 million in Q4 2024, with full-year R&D expenses reaching $93.1 million compared to $31.2 million in the previous year [12][16]. - General and Administrative (G&A) expenses for Q4 2025 were $6.4 million, compared to $2.4 million in Q4 2024, with full-year G&A expenses totaling $20.4 million [12][16]. - The net loss for Q4 2025 was $31.9 million, slightly higher than the $30.1 million loss in Q4 2024, with a total net loss of $127.4 million for the full year [12][16].

Core Insights - The conference call is focused on the Novartis Immunology Portfolio Update, indicating a strategic emphasis on immunology within the company's product offerings [1] Group 1 - The call is being recorded and will be available for later access on the company's website, highlighting transparency and investor engagement [1] - Ms. Isabella Zinck from Investor Relations is leading the call, suggesting a structured approach to investor communication [1]

Company Overview - argenx SE (NASDAQ:ARGX) is enhancing its position in autoimmune therapies with the rapid growth of its flagship treatment, Vyvgart, which is available in both intravenous and subcutaneous forms [2] Product Development - The launch of the Vyvgart subcutaneous prefilled syringe in 2025 has been a significant highlight, gaining popularity as a convenient alternative to infusions, particularly in chronic inflammatory demyelinating polyneuropathy (CIDP) [3] - Over 2,500 patients have already started treatment with Vyvgart in CIDP this year, indicating strong adoption in the U.S. market [3] - Additional approvals for Vyvgart in Japan and Canada are anticipated by the end of the year, which will further expand its global presence [3] Market Potential - Vyvgart is positioned as one of the fastest-growing biologics in generalized myasthenia gravis (gMG) and other autoimmune diseases, with analysts forecasting multibillion-dollar peak sales [4] - Upcoming Phase 3 trial results in late 2025 and early 2026 for seronegative gMG, ocular and pediatric MG, and primary immune thrombocytopenia (ITP) could lead to broader label expansions and reinforce its status as a standard of care [4] Pipeline Expansion - Beyond Vyvgart, argenx SE is developing a diverse pipeline that includes early-stage candidates such as empasiprubart, ARGX-109, and ARGX-119 targeting autoimmune and rare neuromuscular diseases [5] - The company is also exploring new modalities through partnerships, including a recent collaboration with Unnatural Products to create oral peptide therapies [5]